Pyramid Analytics expands AI-driven Decision Intelligence with new OpenAI integration
20.3.2023 15:07:00 EET | Business Wire | Press release
Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, announced today at the Gartner Data & Analytics Summit in Orlando, Florida, that the Pyramid 2023 release extends its already category-leading, AI-driven augmented capabilities with the integration of GPT (generative pre-trained transformer) AI technology from OpenAI—the company behind ChatGPT and DALL-E 2—throughout the platform, interoperating with its deep set of current AI technologies.
The release harnesses the new GPT AI engines to drive complex logic, data science, and machine learning code generation; AI-driven storytelling capabilities; and even AI-assisted design templates and colors. The effort extends Pyramid’s broader vision to enable and drive adoption across the enterprise by empowering all users to solve data-centric business problems through no-code and AI-assisted analytics and decision intelligence.
Key facts about Pyramid’s OpenAI integration
OpenAI is integrated throughout the Decision Intelligence Platform—including the data preparation, data science, the business analytics and spreadsheet modules, and the storyboard and publication designer modules.
- In data preparation: OpenAI can be used to generate SQL, DAX, and MDX code automatically for complex data extraction queries.
- In data science: OpenAI can be used to generate Python and R code automatically to drive machine learning logic.
- In spreadsheets: OpenAI can be used to build spreadsheet formulas for users constructing business models.
- In storyboarding and publications: OpenAI can be used to generate designs for content and graphics.
Separately, OpenAI can be used with existing natural language querying (NLQ) engines to drive and enhance broader insights on enterprise-specific data, ultimately improving the existing tools for delivering automated storytelling and textual analysis.
Market recognition
Pyramid has long been recognized as an innovator in the decision intelligence and analytics space. The company’s Decision Intelligence Platform was ranked #1 —by leading analyst firm Gartner—for “Augmented Analytics” in the 2022 Gartner Analytics and Business Intelligence (ABI) Critical Capabilities report.
Other leading analysts—such as 451 Research , Ventana Research , Dresner Advisory Services , and BARC —recognize Pyramid for its platform-based approach to no-code capabilities and AI/augmented analytics to enable all user types to drive sophisticated analytics easily. Critically, Pyramid’s existing augmented capabilities (NLQ, Chatbot, Smart Insights, Smart Model, Auto Discovery, Fill in the Blanks, Explain, etc.) uniquely operate directly on enterprise data without data duplication, custom models, proprietary data layers, or specialized data treatments.
Demos
Click here to schedule a demo of the Pyramid Decision Intelligence Platform and to learn more about OpenAI on the platform.
Quotes
Avi Perez, CTO and Co-Founder, Pyramid Analytics : “By integrating OpenAI throughout the Pyramid Decision Intelligence Platform, we are extending our existing AI and augmented capabilities with the latest generative AI tech, transforming—and simplifying—the decision-making experience further. As a no-code/low-code platform, Pyramid is designed to extend advanced analytics—from descriptive to predictive to prescriptive—for non-technical businesspeople, allowing them to make informed decisions that drive business outcomes.”
Omri Kohl, CEO and Co-Founder, Pyramid Analytics: “At Pyramid, we believe the key to widespread adoption of data analytics requires an analytics experience that meets different people’s needs, regardless of their technical skills or analytics aptitude. By strategically integrating generative AI technologies like OpenAI, we are taking our AI vision to the next level.”
About Pyramid Analytics
Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005287/en/
Contact information
Pyramid Analytics
Pete Vomocil
SVP, Global Marketing, Pyramid Analytics
pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom